Oocyte versus embryo cryopreservation for fertility preservation in cancer patients: guaranteeing a women's autonomy.

Abstract

The increasing incidence of cancer, combined with higher survival rates in reproductive-aged women is generating growing scientific interest in the application of fertility preservation (FP) technologies for oncological patients [1, 2]. However, less than 5 % of these patients actually preserve their future fertility prior to treatment [3]. Upon examination of the extensive literature, a perception emerges that oocyte cryopreservation is not clearly indicated over embryo cryopreservation for FP. This misconception potentially generates confusion, reluctance, and doubts in the minds of ethics.